focus -WSS

focus

author：hotspot 2025-09-28 00:47:55 - browse：348

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

WSS

The health care issue Democrats can’t solve: hospital reform

Congress gives doctors Medicare pay bump

How to convince healthy people to buy insurance

Congress gives doctors Medicare pay bump

Prime Medicine says its gene editing passes test in monkeys

How to fix the rural physician shortage in the U.S.

Wikipedia

focus

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Obesity now affects over 1 billion people worldwide, study finds

Walensky prepares to leave CDC — and Congress — behind

How to address the problem of discarded donor organs

Moonlake's readout produced a cash windfall. Risks remain

How to address the problem of discarded donor organs

In age of alternative facts, a scholarly course on calling out crap

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Virginia high school admissions case could be legal follow

How neuroscience research could help beat back brain cancer

knowledge

Gene therapy’s promise and the high cost of hope

How neuroscience research could help beat back brain cancer

Humans aren't the only ones with an imagination. Rats have it too

Gene therapy’s promise and the high cost of hope

Lung cancer screening guidelines updated for cigarette smokers

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

leisure time

focus

entertainment

Wikipedia